IPO4U — Indian IPO GMP & Intelligence Platform
Quick Jump
Use ↑ ↓ to navigate · Enter to openEsc to close
Open IPOs
UpcomingMainboardBSE, NSE

Integris Medtech IPO

Integris Medtech IPO on BSE, NSE. Opens 27 Nov 2026 and closes 1 Dec 2026. Allotment 2 Dec 2026. Listing 4 Dec 2026.

View financials

Price Band

—

Bookbuilding IPO

Lot Size

—

Issue Size

—

Fresh: ₹600.00 Cr

Latest GMP

₹0

IPO Timeline & Milestones

All dates anchored to Indian Standard Time (IST)

Subscription Quota Allocation

SEBI Category Reservation Breakdown

Allocation Distribution100% Total Issue
Retail (10%)QIB (75%)HNI / NII (15%)

10%

Retail Investors

Up to ₹2,00,000

75%

QIB Quota

Institutional FIs / MFs

15%

HNI / NII Quota

Above ₹2,00,000

Grey Market Premium (GMP)

At Par / Neutral

₹0

Quote observed

Est. Listing Price—
Est. Gain / Lot—

Upper Price Band

—

Retail Lot Size

—

Min. Investment (1 Lot)

—

Est. Lot Value

—

Grey market quotes are unofficial, unregulated sentiment indicators and do not guarantee listing returns.

Historical GMP Trend

Chronological grey market premium movements

4 Quotes
22 Nov 2026₹0
Range change: ₹0
20 Nov 202621 Nov 202622 Nov 2026
Observation DateGMP PremiumDaily TrendExpected ListingRecorded At
22 Nov 2026₹00—22 Nov 2026, 8:34 am
21 Nov 2026₹00—21 Nov 2026, 6:50 pm
21 Nov 2026₹00—21 Nov 2026, 5:43 am
20 Nov 2026₹0——20 Nov 2026, 5:12 pm

Sector Benchmark · Pharmaceuticals & Healthcare

Historical Listing-Day Performance

Listing-day debut returns compared against issue price across healthcare peers.

Sector Avg. Gain

+16.7%

Across 6 sector peers

Median Debut

+19.4%

Typical listing return

Positive Debuts

6/6

100% listed above issue

Top Sector Debut

+31.4%

Emcure Pharmaceuticals

Listing GainSector Avg (+16.7%)
CompanyIssue PriceListing PriceListing Gain
Emcure Pharmaceuticals
₹1,008₹1,325+31.4%
Concord Biotech
₹741₹900+21.5%
Mankind Pharma
₹1,080₹1,300+20.4%
Sai Life Sciences
₹549₹650+18.4%
Akums Drugs & Pharma
₹679₹725+6.8%
₹693₹706+1.9%

Combines 1 tracked listed Pharmaceuticals & Healthcare peer with historical NSE/BSE sector IPO debuts. Historical listing-day gains are shown for educational sector context only and do not guarantee future listing performance.

Integris Medtech IPO Financials

Restated Consolidated

Period Ended30 Jun 202531 Mar 202531 Mar 202431 Mar 2023
Assets4,019.623,641.342,989.202,553.87
Total Income508.931,959.581,582.261,369.66
Profit After Tax267.5770.68-4.88-40.54
EBITDA78.73309.40190.45168.82
NET Worth3,889.992,752.522,681.022,629.52
Reserves and Surplus2,299.841,150.741,135.711,073.12
Total Borrowing793.421,729.46813.10556.54

Amount in ₹ Crore

Financial Highlights

Key performance metrics from audited statements

Revenue

₹1,959.58 Cr

Profit After Tax (PAT)

₹70.68 Cr

Fresh Issue

₹600.00 Cr

Shareholding Structure

CategoryPre IPOPost IPO
Promoter and Promoter Group83.24%—
Public16.76%—
Total100%—

Company Promoters Evercure Holdings Pte.Ltd., Medicore Holdings Pte.Ltd., Gurmit Singh Chugh and Punita Sharma.

About Integris Medtech

Company overview and operations summary

Incorporated in 2008, Integris Medtech Ltd operates as a diversified global medical products and laboratory solutions company. The company develops, manufactures, commercialises, and sells a broad portfolio spanning cardiovascular devices, clinical diagnostics, and scientific laboratory solutions. It maintains manufacturing facilities across three geographies—India, Germany, and the Netherlands—enabling a resilient global supply chain and regulatory proximity. The company serves over 65 international markets across India, Europe, and Southeast Asia, catering to a customer base exceeding 9,500 laboratories and 2,000 hospitals and cathlabs. Its product portfolio comprises more than 22,000 SKUs across over 200 brands. The business is structured into two core divisions: one focusing on laboratory and hospital solutions in Asia (India, Singapore, Thailand, Malaysia, Philippines) serving both public and private sectors, and another concentrating on cardiovascular products in Europe under proprietary brands like Chrome and Protégé. The Rest of World segment spans the Middle East, Africa, and Latin America. As of June 30, 2025, the company employed 1,879 personnel, including sales, service, and application specialists, and had supported more than 15,000 patients across 100+ clinical trial sites globally, reinforcing its commitment to clinical evidence and innovation. The promoter group includes Evercure Holdings Pte. Ltd., Medicore Holdings Pte. Ltd., Gurmit Singh Chugh, and Punita Sharma.

Integris Medtech IPO Review

Company analysis, investment strengths and risk factors

Integris Medtech Ltd, incorporated in 2008, is a diversified global MedTech company operating across cardiovascular devices, clinical diagnostics, and scient…

Read full IPO review

Compare issue dates, price bands, and sentiment with other active public issues.

View all Upcoming IPOs